Delcath Posts $0.17 EPS, Beating Estimates by $0.26 on $35.1M Revenue

Delcath Systems reported $0.17 in earnings per share for the quarter on Monday, beating the consensus estimate of a $0.09 loss by $0.26. The surprise came with strength on the top line too: revenue reached $35.10 million against a consensus estimate of $25.99 million — a gap of more than $9 million.

The numbers behind the headline show a company operating right at breakeven. Delcath posted a return on equity of 0.46% and a net margin of 0.56%. Thin margins, yes. But positive ones, where analysts expected a loss.

What did the market and the metrics show?

Shares of DCTH opened at $14.93 on Monday. The firm carries a market cap of $518.06 million, a price-to-earnings ratio of 1,494.49 and a beta of 0.62, signaling low volatility relative to the broader market.

The trading picture is similarly concrete:

• 50-day moving average: $15.45
• 200-day moving average: $12.44
• 52-week range: $8.12 to $17.42

The stock opened Monday below its 50-day average but well above its 200-day line, and it sits roughly 14% off its 52-week high. In plain terms: the market had already priced in momentum, and the earnings beat arrived into that strength.

How are analysts reacting?

The research desk has moved in both directions since August. Zacks Research lowered Delcath from a "strong-buy" rating to "hold" in a report on Tuesday, October 6. Weiss Ratings cut the stock from "hold (c)" to "hold (c-)" on Wednesday, October 28.

Others went the other way:

• HC Wainwright reissued a "buy" rating and raised its price objective to $32.00 from $30.00 on Friday, August 7
• Wall Street Zen upgraded the shares from "hold" to "buy" on Saturday, August 8
• BTIG Research lifted its target price to $21.00 from $17.00 and kept a "buy" rating on Thursday, August 6

The tally now stands at two Buy ratings and two Hold ratings. According to MarketBeat data, the stock carries an average rating of "Moderate Buy" with a consensus target price of $26.67 — roughly 78% above Monday's opening print.

The takeaway: the beat was unambiguous, but the analyst community is divided on what pays off from here.

What drives the business behind the beat?

Delcath Systems is a medical technology company focused on liver-directed cancer treatments. It develops and commercializes systems that deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

In the United States, its primary product is the HEPZATO KIT, which pairs the company's proprietary hepatic delivery system with melphalan hydrochloride for injection. Regulators have approved HEPZATO for adult patients with unresectable metastatic uveal melanoma involving the liver — without extrahepatic disease, or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath sells the corresponding system under the CHEMOSAT brand.

A $35.1 million quarter, positive margins and a split analyst bench: the revenue engine is running ahead of expectations, and the next reports will show whether margins follow.